Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan versus enalapril for acute decompensated heart failure with reduced ejection fraction
ChiCTR2000034822Phase 4Not yet recruiting
- Sponsor
- Chongqing Kanghua Zhonglian Cardiovascular Hospital
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of sacubitril + valsartan and enalapril in heart failure (HF) (2 arms), sponsored by Chongqing Kanghua Zhonglian Cardiovascular Hospital. Primary endpoints: Death from cardiovascular causes and Rehospitalization for heart failure. Planned start Aug 2020; status: not yet recruiting.
02
Drugs
sacubitril + valsartanenalapril
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on ChiCTR2000034822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000034822.